Suven Life Scie.

Suven Life Sciences reported a strong sequential performance in Q4 FY19, with revenue increasing by 90% quarter-on-quarter and Profit After Tax (PAT) surging by 170% quarter-on-quarter. For the full fiscal year FY19, the company achieved a top-line growth of 6% year-on-year, reaching Rs. 645 crore. However, the bottom-line for FY19 declined by 5% year-on-year, primarily attributed to changes in product mix and a slight increase in raw material costs, particularly from Chinese sources.

The company provided optimistic guidance for its core businesses for FY20. Commercial CRAMS revenue is projected to increase significantly to Rs. 130 crore, up from Rs. 80 crore in FY19. Overall Core CRAMS, including commercial CRAMS, is expected to achieve a growth rate of 10%-15% next year. The Specialty Chemicals segment, which saw a 40% growth in FY19 to Rs. 216 crore (including a new commercial molecule), is anticipated to maintain its revenue at the Rs. 200-215 crore level in FY20.

A major highlight was the completion of the Phase 2 clinical trial for SUVN-502 (Masupirdine), with the last patient visit concluded. The company is currently in the process of database lock and data cleaning, with top-line results expected to be presented at the International Alzheimer's conference in Los Angeles in July 2019, or potentially by the end of June. Management emphasized the 'black and white' nature of the data, which will determine future development and potential out-licensing deals, with historical valuations for similar molecules ranging from $100-150 million upfront and $500-800 million in milestones.

Suven Life Sciences has made a strategic investment of USD 35 million for a 25% minority stake in Shore Pharma, a virtual pharma company that was previously bankrupt but holds 85-90 commercialized ANDAs. This investment is aimed at gaining access to a marketing channel for Suven's own ANDAs and facilitating backward integration for development and supply. While no immediate revenue accretion is expected, the human health division of Rising Pharma is projected to start at $200 million in revenue and grow to $340-$360 million within a couple of years.

The company outlined substantial R&D investments for FY20. Standalone R&D for clinical trials is budgeted at $10 million, with specific allocations of $4-$5 million for SUVN-502 and $6-$7 million for SUVN-G3041. Additionally, $10 million each is earmarked for Neuroscience R&D in the USA and India, totaling a $20 million R&D budget. CAPEX for FY20 is projected at Rs. 200 crore, spread over 12-15 months, primarily for a new formulation development center and an additional block in Vizag, with maintenance CAPEX estimated at Rs. 30-40 crore.

The demerger process is progressing, with No-Objection Certificates (NOCs) received from regulatory bodies. The company is in the process of filing with the NCLT and anticipates the demerger to be completed by Q3 FY20, with listing expected before December. For FY20, Suven Life Sciences guided for a 20% growth in its standalone bottom-line. The tax rate is expected to remain in the 33%-35% range, operating under a full tax regime.

Beyond SUVN-502, SUVN-G3041 is in the final stages of FDA protocol filing, with patient enrollment for narcolepsy trials expected to begin next quarter, a process that will take 12-15 months. Other compounds, SUVN-911 and SUVN-D4010, are undergoing long-term safety studies and are targeted for proof-of-concept by 2020. The company continues to work on a diverse pipeline of molecules across various therapeutic areas.